Play Earnings CallPlay Earnings Call
Lexicon Pharmaceuticals, Inc. (LXRX) 44th Annual J.P. Morgan Healthcare Conference January 15, 2026 3:00 PM EST
Company Participants
Michael Exton – CEO & Director
Craig Granowitz – Senior VP & Chief Medical Officer
Conference Call Participants
Alex Morrison
Presentation
Alex Morrison
Good afternoon, everyone. Welcome to the 44th Annual JPMorgan Healthcare Conference. My name is Alex Morrison. I’m an associate on JPM’s health care team. Today, it’s my pleasure to introduce Lexicon Pharmaceuticals. We’ll have CEO, Mike Exton, speak; as well as Craig, Chief Medical Officer; and Scott, Chief Financial Officer, on stage for Q&A.
Michael Exton
CEO & Director
Great. So thanks so much, Alex, and thanks to JPMorgan for the invitation to present the Lexicon story. So for those of you who are unfamiliar with Lexicon — let me go back. I’ll be making some forward-looking statements. Please refer to the SEC filings for further details.
But Lexicon was founded 30 years ago with a bold ambitious plan at the time around before the human genome was described, before the mouse genome was even described to take 5,000 genes and create knockout mouse lines for all of those genes. Creating those mouse lines, then running them through a battery of tests to see what would be the impact of those genes. And as a result, they identified 200 genes of interest.
And fast forward through the Lexicon story. And we’re pleased that over that time, we’ve had over 80 clinical trials looking at a number of new medicines and has resulted in the approval of 2 medicines in the United States. And — and the approval and commercialization of INPEFA and taking new novel mechanisms into the clinic. We now have a medicine for non-opioid approach in neuropathic pain and a new non-incretin mechanism in obesity.
The
